FDA Accepts Virtual Life Management® for Evaluation Into The MDDT Pilot Program.

Virtual Twin of a cardiac rhythm electrical lead.

Virtual Twin of a cardiac rhythm electrical lead.

April 1, 2015, Brentwood, TN-The Food and Drug Administration (FDA) will evaluate VEXTEC’s Virtual Life Management (VLM®) for certification as a Medical Device Development Tool (MDDT). The goal of the MDDT pilot program is to assess and refine the qualification process for tools used to develop and evaluate medical devices. The pilot program is limited to 15 tool developers. The FDA stated that VEXTEC’s, “proposal was accepted because your tool is at a mature stage of development and meets a public health need (major efficiencies to be gained in device development and evaluation time).” Read more